Drug costs In the opening weeksof 2019, pharma companies have boosted list prices on hundreds oftreatments, including widely used painkillers and cardiovasculardrugs. (Photo: Shutterstock)

Two years ago, fear that Donald Trump would clamp down on drug prices roiled the healthindustry's biggest annual gathering.

Now, pushback on prices has become part of a newnormal for which many pharmaceutical executives have developed areliable script: Drug costs should reflect the value treatments deliver to patients, they say.Savings shouldn't come at the expense of innovation. And thecompanies they run have been restrained and transparent in takingprice increases.

Continue Reading for Free

Register and gain access to:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.

Core and Group Health
Health Care Reform
Cost-Containment